Clinical Trial Update: A Study Comparing Upadacitinib (ABT-494) to Placebo in Adults With Rheumatoid Arthritis on a Stable Dose of Conventional Synthetic Disease-Modifying Antirheumatic Drugs (csDMARDs) Who Have an Inadequate Response to csDMARDs Alone [Phase 3]

View source ↗

Summary

Phase 3 trial comparing upadacitinib to placebo in adults with rheumatoid arthritis on csDMARDs who had an inadequate response, results posted in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis

Drugs mentioned

• Upadacitinib (upadacitinib)

Snippet

Sponsor: AbbVie | Conditions: Rheumatoid Arthritis | Phase 3 | Status: COMPLETED | Results posted: 2019-10-07